Related Experiment Video
Updated: Jun 19, 2026
03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Omega-3 fatty acids and heart failure.
Roberto Marchioli1, Maria Giuseppina Silletta, Giacomo Levantesi
1Consorzio Mario Negri Sud, Via Nazionale, Santa Maria Imbaro, Italy. marchioli@negrisud.it
Current Atherosclerosis Reports
|October 27, 2009
Summary
Omega-3 polyunsaturated fatty acids (PUFA) significantly reduced mortality and hospital admissions in chronic heart failure patients. Marine fish oils may offer protection through antiarrhythmic effects and influencing heart failure progression.
Area of Science:
- Cardiology
- Nutritional Science
- Pharmacology
Background:
- Omega-3 polyunsaturated fatty acids (PUFA), specifically eicosapentaenoic acid and docosahexaenoic acid, have demonstrated protective roles in coronary heart disease for decades.
- Chronic heart failure (HF) remains a significant cardiovascular challenge, necessitating effective therapeutic strategies.
Purpose of the Study:
- To review current clinical and experimental evidence on the cardioprotective effects of n-3 PUFA.
- To specifically examine the impact of n-3 PUFA on patients with chronic heart failure (HF).
- To explore the pathophysiologic mechanisms underlying the benefits of n-3 PUFA in HF.
Main Methods:
- Review of recent clinical trials and experimental studies.
- Focus on findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure (GISSI-HF) study.
- Analysis of data concerning mortality and hospital admissions in HF patients.
Main Results:
- The GISSI-HF study demonstrated that daily n-3 PUFA supplementation (850-882 mg/d) reduced mortality and cardiovascular hospital admissions in patients with chronic HF on standard therapies.
- These findings suggest that marine fish oils confer protection in HF.
Conclusions:
- The favorable effects of n-3 PUFA in HF patients are likely mediated by antiarrhythmic actions.
- n-3 PUFA may also influence mechanisms involved in the progression of heart failure.
- Marine fish oils represent a potentially valuable therapeutic adjunct in managing chronic heart failure.
Related Concept Videos
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
03:38Structure of Lipids
Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic birds and...